Substantial reductions in IHD and cerebrovascular diseases highlight potential contributions of advances in diagnostic and therapeutic innovation including treatment of hypertension, intensive management of acute stroke (e.g. CT-scan, thrombolytic therapy), and improvement in the management of myocardial infarction (e.g. β-blockers, ACE-inhibitors) [33, 35]. Here, ACE is linked to myocardial infarction.